evenfolio

Healthcare · NSE: SUPRIYA

Supriya Lifescience

Q2 FY27 earnings and concall highlights

Price as of 16 Nov 2026
622.30−1.55%

Q2 FY27 earnings call · Guided by management

Call held 6 Nov 2026 · Read the filing on NSEFiling

₹1,000​CrRevenue · FY27Wagh · p. 4
₹160–200​CrAmbernath breakeven revenue · AmbernathRaghunathan · Q&A · p. 14
₹35.4​CrCapex · H1 FY27Raghunathan · p. 5
23–25​%EBITDA margin · FY27Wagh · p. 4
M.Cap
₹5,008Cr
P/E
28.3×
1Y return
−21.20%
From 52W high
−42.6%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · standalone · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue206200+3.2%190+8.7%
EBITDA4573-37.5%47-4.3%
EBITDA margin22.0%36.4%-1434 bps25.0%-300 bps
PBTProfit before tax3868-44.7%41-7.4%
Net profit2950-42.0%24+21.7%
EPS (₹)3.636.27-42.1%2.99+21.4%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

Guidance

Revenue growth · long term20%Revenue growth of 20% plus guided for next 3-4 years
Revenue · FY27Rs 1,000 CrRevenue milestone of Rs 1,000 crore targeted by FY27
EBITDA margin · FY2723-25%cutEBITDA margin guidance revised down to 23%-25%

More figures from the call

Company · Guidance
25​%EBITDA margin · FY27
“Yes. So, we are looking at about 25% for the remaining part of FY '27. So, for the full year, it would be around 25%.”
Saloni Wagh · Managing Director · Q&Ap. 6
Ambernath · Capacity
₹450–500​CrAmbernath revenue potential · once we have the EU approval
“Ambernath is also one area which can be a big growth driver because once we have the EU approval, that site is designed to generate at least INR450 crores, INR500 crores of revenue moving forward.”
Saloni Wagh · Managing Directorp. 9
Ambernath · Capex
1–1.5​yearsAmbernath ramp-up time · 1, 1.5 years
“And we believe that around 1, 1.5 years would be the timeline in which we will be able to get Ambernath to a meaningful number.”
Krishna Raghunathan · Chief Financial Officer · Q&Ap. 14
module E · Capacity
1,100​tonnesAnesthetic API capacity
“So, we can take up the product to almost 1,100 tonnes, that capacity we have already created.”
Saloni Wagh · Managing Director · Q&Ap. 16
module E · Capacity
4–5​yearsTime for customer to reach maximum capacity · 4, 5 years
“So, the maximum capacity, of course, will take 4, 5 years for the customer to reach.”
Saloni Wagh · Managing Director · Q&Ap. 16
Ambernath · Margins and costs
₹60​CrAmbernath expenses · FY27
“So, I think that would still remain a large impact on the margin because we are looking at almost INR60 crores of expenses from Ambernath for the full year.”
Saloni Wagh · Managing Directorp. 7

In short

  1. 01FY27 EBITDA margin guidance cut to 23%-25%, citing product mix, Ambernath ramp-up and raw material prices.
  2. 02Full-year FY27 EBITDA margin expected around 25%.
  3. 03FY27 revenue target of Rs 1,000 crore kept; management says it is very confident.
  4. 04Q2 FY27 revenue was Rs 206 crore (+3.2%); EBITDA Rs 45 crore (-37.5%), margin 22%.
  5. 05LATAM products reclassified as controlled substances; customers need import permits taking at least 4-5 months.
  6. 06Ambernath costs about Rs 60 crore this year; EU audit due in November; FY27 revenue from site may be near zero.
  7. 07Revenue growth of 20% plus guided for the next 3-4 years; no margin guidance yet for next year.
  8. 08Large anesthetic CMO contract described as very close to signing.

Capex

Ambernath: EU audit of Ambernath scheduled for November, starting next week

Saloni Wagh · Managing Director · Q&A · p. 6
“But yes, once this year is completed, Ambernath comes into operation, we are scheduled for an EU audit in the month of November for Ambernath, in fact, starting next week.”

Capex mainly on Ambernath, maintenance, Ribo block and formulation plant

Krishna Raghunathan · Chief Financial Officer · p. 5
“This was largely driven by spends on the Ambernath facility along with the maintenance capex and smaller projects, including the Ribo block and formulation plant requirements.”

Capacity

Ambernath: Ambernath has injection, tablet, capsule and liquid inhalation lines

Saloni Wagh · Managing Director · p. 9
“We have injection lines, we have tablets, capsules, and liquid inhalation lines.”

Order book

CMO, CDMO: Two to three large CMO/CDMO opportunities under discussion

Saloni Wagh · Managing Director · p. 9
“We are already discussing two, three very large opportunities in this space for API as well as finished formulation.”

CMO: Large anesthetic CMO contract very close to signing; announcement hoped in coming weeks

Saloni Wagh · Managing Director · p. 7
“Plus, one large CMO opportunity that we are discussing, on the anesthetic project that is very close to signing. Hopefully, in the next coming weeks, we'll be able to announce that.”

Order book in place to support revenue; inventory acknowledged

Saloni Wagh · Managing Director · Q&A · p. 7
“Like you mentioned rightly, there is a lot of inventory. We do have the order book in place.”

Ambernath: Small ROW contract from Ambernath with a different customer

Saloni Wagh · Managing Director · Q&A · p. 16
“It's a different customer. It's not a very large commercial contract. On commercial scale, it is quite small, but it's just a breakthrough for us to enter the ROW market.”

anesthetics: Anesthetic product to move to exclusive model once large contract signed

Saloni Wagh · Managing Director · p. 17
“So once the contract for this large customer is done, then we would be moving to an exclusive model, and we will only be working with this particular customer for the entire anesthetic product.”

Segments

Three growth drivers named; first is the baseline business in regulated markets

Saloni Wagh · Managing Director · Q&A · p. 8
“So, we have 3 main growth drivers for achieving this 20% growth in revenue. Number one is the existing baseline business which continues to remain strong, and it continues to grow across regulated markets.”

Exports: Exports 80% of Q2 revenue; Europe 43%, Asia 36%, LATAM 12% of exports

Shivani Wagh · Joint Managing Director · p. 4
“Exports continued to be a key contributor to the business, accounting for 80% of revenue in Q2 FY '27. Within exports, Europe contributed 43%; Asia, 36%; and LATAM, 12%.”

LATAM: LATAM share had risen from 10% to 21%, back to 12% this quarter

Saloni Wagh · Managing Director · Q&A · p. 12
“If you look at the historic quarters also, LATAM had scaled almost from 10% to 21%, which has gone back to 12% in this quarter.”

Ambernath: Possible upside next year if Ambernath commercialises right after EU audit

Saloni Wagh · Managing Director · Q&A · p. 12
“If Ambernath moves into commercialization immediately after the EU audit, then yes, there could be an upside to that.”

Statins intermediate: Statins intermediate expected to add significant revenue next year

Saloni Wagh · Managing Director · Q&A · p. 17
“I think next year it would definitely add significant revenue to our top line because by then, I think all the contracts would be in place and all the customers, we have already approved of the product so the quality and everything is done.”

Demand

anesthetics: Anesthetic molecule global market about $400-500 million

Saloni Wagh · Managing Director · p. 12
“For example, the anesthetic molecule itself is at about $400 million, $500 million and it sort of continues for the other products as well.”

Statins intermediate: Only fully integrated producer of this API in India; China is main competitor

Saloni Wagh · Managing Director · Q&A · p. 17
“So, we are still the only fully integrated producer of this API in India. And yes, China is our biggest competitor.”

ADHD: ADHD API market potential about $100-150 million

Saloni Wagh · Managing Director · Q&A · p. 17
“At the API level, I think the market potential is about $100 million, $150 million.”

Products launched in FY26 seeing traction

Shivani Wagh · Joint Managing Director · p. 4
“We are also seeing encouraging traction in the products launched during FY '26, which gives us confidence in the strength of our product pipeline and the opportunities ahead.”

Margins and costs

Q2 FY27 EBITDA Rs 45 crore, down 37.5%, margin 22%

Shivani Wagh · Joint Managing Director · p. 3
“EBITDA for the quarter stood at INR45 crores, a decline of 37.5%, with an EBITDA margin of 22%.”

H1 FY27 EBITDA Rs 93 crore vs Rs 124 crore, down 25.3%; margin 23.4%

Krishna Raghunathan · Chief Financial Officer · p. 5
“EBITDA stood at INR93 crores as against INR124 crores in H1 FY '26, a degrowth of 25.3% year-on-year. EBITDA margins are at 23.4% for H1 FY '27.”

Margin dip called not permanent; expected to correct over next couple of quarters

Saloni Wagh · Managing Director · Q&A · p. 5
“The margin profile dip is not on a permanent basis. This is more of a transient midterm kind of a situation, which we are expecting to correct over the next couple of quarters.”

Typical margin 34%-35%; current margin down 11%-12%

Saloni Wagh · Managing Director · Q&A · p. 6
“So, if you look at our typical margin profile, it ranges anywhere between 34% to 35%. And if I look at the current margin profile, it's down by 11% to 12%.”

Ambernath: About 6% of margin drop attributed to Ambernath expenses

Saloni Wagh · Managing Director · Q&A · p. 6
“So, the main split across this 11% to 12%, I would say 6% is because of the expenses of Ambernath, which were not there for the last year.”

Debt and working capital

No working capital limits used except letters of credit and bank guarantees

Krishna Raghunathan · Chief Financial Officer · p. 5
“On borrowing, we would like to report that for the full year we have not utilized any working capital limits except for letter of credit and bank guarantees.”

Acquisitions and new business

anesthetics: Anesthetic product received CEP; USDMF approval expected soon

Saloni Wagh · Managing Director · p. 7
“A lot of effort is ongoing for the newer products specifically like the anesthetic product that we launched, we recently got the CEP. So, we are trying to break through the Europe market. We are also getting USDMF approval for that product very soon.”

Ambernath: Two anesthetic liquid inhalation products launched from Ambernath in Q2 FY27

Shivani Wagh · Joint Managing Director · p. 4
“Coming to new product launches, as guided in our Q1 FY '27 earnings call, we launched 2 new anesthetic liquid inhalation products from our Ambernath facility during Q2 FY '27.”

ADHD: Two ADHD products in the pipeline

Shivani Wagh · Joint Managing Director · p. 4
“In addition, we have 2 ADHD products in the pipeline, which will further expand our portfolio and contribute to growth as they are commercialized.”

whey protein: Whey protein samples approved by customers; commercial orders expected to start

Saloni Wagh · Managing Director · Q&A · p. 16
“We have been successfully able to send out the samples and customers have approved of. And we are looking at starting of the commercial orders.”

contrast media: Contrast media product launch hoped by next quarter

Saloni Wagh · Managing Director · Q&A · p. 16
“And in terms of the contrast media, I think we are very close to launching that product. Hopefully, by next quarter, we would be in a position to launch it and at least do a commercial scale up at plant.”

Management

Mangesh Vaze joins as Chief Operating Officer

Shivani Wagh · Joint Managing Director · p. 4
“Before I move on, I would like to take a moment to welcome Mr. Mangesh Vaze, who has joined us as our Chief Operating Officer.”

Risks

LATAM: Quarter sales hit by regulatory changes in LATAM market

Shivani Wagh · Joint Managing Director · p. 3
“Our sales performance during the quarter was impacted by regulatory changes in the LATAM market, which affected demand for certain products.”

LATAM: High-margin products in LATAM recently classified as controlled substances

Saloni Wagh · Managing Director · Q&A · p. 5
“As far as the regulatory change goes, a lot of our high-margin controlled products in LATAM have recently been categorized as controlled substances.”

Ambernath: Ambernath revenue this year may be close to zero due to approval delay

₹0​Cr
Saloni Wagh · Managing Director · p. 10
“So, the revenue generation, which was to happen from Ambernath for this financial year might be closer to 0 for this year now because of the delay in the regulatory approvals.”

Ambernath: Ambernath EU audit pushed to third quarter

Saloni Wagh · Managing Director · p. 10
“But because the EU audit is getting pushed and the EU audit is now happening in the third quarter, it's scheduled for next week.”

Growth may stay nonlinear across quarters

Shivani Wagh · Joint Managing Director · p. 4
“As we have highlighted previously, growth may remain nonlinear across quarters as new products scale up, and market conditions evolve.”

Other

Q2 FY27 revenue Rs 206 crore, up 3.2% year-on-year

Shivani Wagh · Joint Managing Director · p. 3
“Revenue for the quarter stood at INR206 crores, registering growth of 3.2% year-on-year.”

Q2 FY27 PAT Rs 29 crore vs Rs 50 crore; PAT margin 14.2%

Krishna Raghunathan · Chief Financial Officer · p. 5
“PAT stood at INR29 crores as against INR50 crores in Q2 FY '26. PAT margin stood at 14.2% for Q2 FY '27.”

H1 FY27 revenue Rs 396 crore vs Rs 345 crore, up 14.8%

Krishna Raghunathan · Chief Financial Officer · p. 5
“For H1 FY '27 revenue from operations stood at INR396 crores as against INR345 crores in H1 FY '26, a growth of 14.8% year-on-year.”

Fully backward integrated products about 74% of total revenue

Shivani Wagh · Joint Managing Director · p. 4
“Products that are fully backward integrated now account for approximately 74% of total revenue, giving us greater control over our supply chain and cost structure.”

H1 FY27 PAT Rs 53 crore vs Rs 85 crore; PAT margin 13.5%

Krishna Raghunathan · Chief Financial Officer · p. 5
“PAT stood at INR53 crores as against INR85 crores in H1 FY '26. PAT margins were at 13.5% for H1 FY '27.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools